Skip to main content
SpringerLink
Log in

Neueste Entwicklungen

Therapiestrategien für Patienten mit Pankreaskarzinom

  • Zertifizierte Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Zusammenfassung

Die Diagnose eines Pankreaskarzinoms ist für die Betroffenen aufgrund der ungünstigen Prognose in aller Regel niederschmetternd. Auch wenn eine Heilung nur selten gelingt, konnte die Prognose in jüngster Vergangenheit durch die Entwicklung neuer Substanzen und Therapieregimes substanziell verbessert werden. So wurden etwa neue Operationstechniken entwickelt und adjuvante Therapieoptionen erprobt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  2. Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Jemal A et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106–30.

    Google Scholar 

  4. Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2013) Krebs in Deutschland 2009/2010. RKI, Berlin 2013.

  5. Hidalgo M. Pancreatic Cancer. N Engl J Med. 2010;362(17):1605–17.

    Article  CAS  PubMed  Google Scholar 

  6. S3-Leitlinie zum exokrinen Pankreaskarzinom. Version 1.0 — Oktober 2013; AWMF-Registernummer. 032/010OL. Langversion; http://www.awmf.org/uploads/tx_szleitlinien/032-010OLl_S3_Exokrines_Pankreaskarzinom_21112013.pdf; abgerufen am 19.08.2016.

  7. Bansal P et al. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology. 1995;109(1):247–51.

    Article  CAS  PubMed  Google Scholar 

  8. Ben Q et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928–37.

    Article  PubMed  Google Scholar 

  9. Preziosi G et al. Obesity and pancreatic cancer. Surg Oncol. 2014;23(2):61–71.

    Article  PubMed  Google Scholar 

  10. Schulte A et al. Cigarette smoking and pancreatic cancer risk: more to the story than just pack-years. Eur J Cancer. 2014;50(5):997–1003.

    Article  PubMed  Google Scholar 

  11. Rhim AD et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Michl P et al. Current concepts and novel targets in advanced pancreatic cancer. Gut. 2013;62(2):317–26.

    Article  CAS  PubMed  Google Scholar 

  13. Rau BM et al. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery. 2012;152(3 Suppl 1):S103–11.

    Article  PubMed  Google Scholar 

  14. Katz MH et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95.

    Article  PubMed  Google Scholar 

  15. Oettle H. Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014;40(9):1039–47.

    Article  PubMed  Google Scholar 

  16. Takada T et al. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology. 1997;44(14):567–73.

    CAS  PubMed  Google Scholar 

  17. Wente MN et al. Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg. 2007;193(2):171–83.

    Article  PubMed  Google Scholar 

  18. Ma S et al. Pancreaticogastrostomy versus pancreaticojejunostomy. J Surg Res. 2014;192(1):68–75.

    Article  PubMed  Google Scholar 

  19. Shen Y et al. Reconstruction by Pancreaticogastrostomy versus Pancreaticojejunostomy following Pancreaticoduodenectomy: A Meta-Analysis of Randomized Controlled Trials. Gastroenterol Res Pract. 2012;2012:627095.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Morera-Ocon FJ et al. Considerations on pancreatic exocrine function after pancreaticoduodenectomy. World J Gastrointest Oncol. 2014;6(9):325–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yekebas EF et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg. 2008;247(2):300–9.

    Article  PubMed  Google Scholar 

  22. Mollberg N et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882–93.

    Article  PubMed  Google Scholar 

  23. Sasson AR et al. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg. 2002;6(2):147–57.

  24. Boggi U et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery. 2009;146(5):869-881.

  25. Callery MP et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727–33.

    Article  PubMed  Google Scholar 

  26. Buc E et al. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol. 2014;12:347.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Briggs CD et al. Systematic review of minimally invasive pancreatic resection. J Gastrointest Surg. 2009;13(6):1129–37.

    Article  PubMed  Google Scholar 

  28. Khorana AA et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541–56.

    Article  PubMed  Google Scholar 

  29. Oettle H et al. Adjuvant chemotherapy with gemcitabine and longterm outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.

    Article  CAS  PubMed  Google Scholar 

  30. Campbell F et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55(3):277–83.

    Article  PubMed  Google Scholar 

  31. Neoptolemos J et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine and capecitabine versus monotherapy gemcitabine in patients with resected pancreatic ductal carcinoma. J Clin Oncol. 2016;34(Suppl):Abstr LBA4006.

  32. Neoptolemos JP et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.

    Article  CAS  PubMed  Google Scholar 

  33. Uesaka K et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, noninferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–57.

    Article  CAS  PubMed  Google Scholar 

  34. Liao WC et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(11):1095–103.

    Article  PubMed  Google Scholar 

  35. Neoptolemos JP et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.

    Article  CAS  PubMed  Google Scholar 

  36. Nanda RH et al. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015;111(8):1028–34.

    Article  CAS  PubMed  Google Scholar 

  37. Tachezy M et al. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer. 2014;14:411.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Blazer M et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153–9.

    Article  PubMed  Google Scholar 

  39. Kunzmann V et al. Intensified Neoadjuvant Chemotherapy with Nab- Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer. Case Rep Oncol. 2014;7(3):648–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Maraveyas A et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48(9):1283–92.

    Article  CAS  PubMed  Google Scholar 

  41. Oettle H et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Helmut Oettle

  2. Klinik für Allgemein- und Viszeralchirurgie, Klinikum Friedrichshafen GmbH, Röntgenstr. 2, 88048, Friedrichshafen, Deutschland

    Thorsten G. Lehmann

Authors
  1. Helmut Oettle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten G. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten G. Lehmann.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen und dass keine potenziellen Interessenkonflikte vorliegen. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oettle, H., Lehmann, T.G. Therapiestrategien für Patienten mit Pankreaskarzinom. Im Focus Onkologie 19, 58–66 (2016). https://doi.org/10.1007/s15015-016-2284-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-016-2284-9

Search

Navigation